Rathor, Naveen
Novo Nordisk (Denmark)
4 papers on CoChat
Most cited papers
- Verified
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine
Chronic Kidney Disease and DiabetesDiabetes Treatment and Management
Cited by 238
- Verified
Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
Rubino, D., Bjorner, J. B., Rathor, N., Sharma, A. M., von Huth Smith, L., Wharton, S., Wadden, T., Zeuthen, N., & Kolotkin, R. L. (2024) · Diabetes, Obesity and Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 56
- Verified
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
Gabe, M. B. N., Breitschaft, A., Knop, F. K., Hansen, M. R., Kirkeby, K., Rathor, N., & Adrian, C. L. (2024) · Diabetes, Obesity and Metabolism
Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity
Cited by 46
- Verified
Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study
Sbraccia, P., Aberle, J., Olsen, A. H., Rathor, N., & Major‐Pedersen, A. (2023) · Diabetes, Obesity and Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free